Maria Sargianou

Dr. Maria Sargianou


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
MSMaria Sargianou
Maria Sargianou
PSPanagiotis Stathopoulos
Panagiotis Stathopoulos
CVChristos Vrysis
Christos Vrysis
ITIva D. Tzvetanova
Iva D. Tzvetanova
MFMatthew Falagas
Matthew Falagas
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics. During the last 2 years from the writing of this article, cefepime/enmetazobactam, aztreonam/avibactam, and sulbactam/durlobactam were approved for use in clinical practice. Cefepime/enmetazobactam targets extended-spectrum β-lactamase (ESBL)-producing Pseudomonas aeruginosa and Enterobacterales. It is indicated for the treatment of patients with complicated urinary tract infections, including pyelonephritis, in Europe and the USA, and also for hospital-acquired pneumonia, ventilator-associated pneumonia, and bacteremia associated with those infections (only in Europe). The antimicrobial spectrum of aztreonam/avibactam includes carbapenem-resistant Enterobacterales. Aztreonam/avibactam is indicated for the treatment of adult patients who suffer from complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis, hospital-acquired pneumonia, and ventilator-associated pneumonia due to aerobic Gram-negative infections with limited therapeutic options. Sulbactam/durlobactam, a combination of 2 β-lactamase inhibitors, is indicated for the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia due to the Acinetobacter baumannii–calcoaceticus complex [including carbapenem-resistant Acinetobacter baumannii (CRAB) infections].

13 August 2025 in Biology
Verified
Journal Article
Open access
PDF file
MFMatthew Falagas
Matthew Falagas
DKDimitrios Kontogiannis
Dimitrios Kontogiannis
MSMaria Sargianou
Maria Sargianou
EFEvanthia M. Falaga
Evanthia M. Falaga
MCMaria Chatzimichali
Maria Chatzimichali
Charalambos MichaeloudesCharalambos Michaeloudes
Charalambos Michaeloudes
Novel infection control practices are necessary to reduce the incidence of healthcare-associated infections (HAIs). Since 2007, probiotic-based cleaning solutions have been proposed as an alternative to traditional methods using disinfectants and detergents in healthcare settings, including hospitals. We conducted a comprehensive search across Google Scholar, PubMed, Scopus, and Web of Science resources. Studies that assessed the reduction in pathogens on surfaces and the emergence of HAIs after the use of probiotic-based cleaning solutions were eligible for evaluation. A total of 16 studies (13 in clinical settings and 3 on experimental surfaces) were included. The Staphylococcus species were most commonly identified before and after the use of probiotic-based cleaning solutions. All studies showed numerically lower pathogen counts and fewer HAIs after using probiotic-based cleaning solutions compared to disinfectants and detergents. Three studies indicated a reduction in antimicrobial resistance genes after use of probiotic-based cleaning solutions. One of these showed statistically significant differences compared to traditional disinfectants (alcohol, amines, and quaternary ammonium compounds) and detergents (non-ionic and anionic surfactants). The results of the included studies suggest the consideration of probiotic-based cleaning solutions for infection control in healthcare systems. However, given the novelty of this approach, further studies are needed to verify the evaluated findings and investigate the short- and long-term effectiveness, and safety of probiotic-based cleaning solutions on infection control practices in healthcare settings.